Special Issue

Advances in Personalized Diagnosis and Treatment of Ophthalmic Diseases

Message from the Guest Editor

This Special Issue aims to showcase cutting-edge research, innovative approaches, and significant developments in the field of personalized medicine applied to ophthalmology. For this Special Issue, we invite original research, commentaries, and reviews that explore various aspects of personalized approaches in ophthalmology. The scope of the Special Issue includes. but is not limited to, the following topics: Integration of genetic, molecular, and imaging biomarkers for individualized disease risk assessment and precise diagnosis: Innovative diagnostic imaging techniques and technologies for improved disease characterization to improve patient outcomes in ophthalmic diseases; Role of artificial intelligence and machine learning in personalized ophthalmology: Digital health technologies for remote monitoring and personalized disease management for teleophthalmology; Individualized drug delivery systems or treatment paradigms for enhanced treatment outcomes; Social and policy implications of personalized medicine in ophthalmology.

Guest Editor

Dr. David Ramsey

- Lahey Department of Surgery, Division of Ophthalmology, UMass Chan Medical School, University of Massachusetts, Burlington, MA 01805, USA
- 2. Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA
- 3. Graduate Faculty, The New England College of Optometry, Boston, MA 02215, USA

Deadline for manuscript submissions

15 February 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/176205

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

